- Home
- PGZ vs INCR Comparison
PGZ vs INCR Comparison
Compare PGZ & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- INCR
- Stock Information
- Founded
- PGZ 2012
- INCR 1994
- Country
- PGZ United States
- INCR Israel
- Employees
- PGZ N/A
- INCR N/A
- Industry
- PGZ Investment Managers
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- PGZ Finance
- INCR Health Care
- Exchange
- PGZ Nasdaq
- INCR Nasdaq
- Market Cap
- PGZ 70.2M
- INCR 84.5M
- IPO Year
- PGZ N/A
- INCR N/A
- Fundamental
- Price
- PGZ $10.54
- INCR $1.56
- Analyst Decision
- PGZ
- INCR
- Analyst Count
- PGZ 0
- INCR 0
- Target Price
- PGZ N/A
- INCR N/A
- AVG Volume (30 Days)
- PGZ 23.0K
- INCR 18.7K
- Earning Date
- PGZ 01-01-0001
- INCR 08-15-2025
- Dividend Yield
- PGZ 12.26%
- INCR N/A
- EPS Growth
- PGZ N/A
- INCR N/A
- EPS
- PGZ N/A
- INCR N/A
- Revenue
- PGZ N/A
- INCR $65,575,323.00
- Revenue This Year
- PGZ N/A
- INCR $69.54
- Revenue Next Year
- PGZ N/A
- INCR $41.75
- P/E Ratio
- PGZ N/A
- INCR N/A
- Revenue Growth
- PGZ N/A
- INCR N/A
- 52 Week Low
- PGZ $8.46
- INCR $1.17
- 52 Week High
- PGZ $10.59
- INCR $2.62
- Technical
- Relative Strength Index (RSI)
- PGZ 59.19
- INCR 57.53
- Support Level
- PGZ $10.45
- INCR $1.43
- Resistance Level
- PGZ $10.54
- INCR $1.50
- Average True Range (ATR)
- PGZ 0.07
- INCR 0.06
- MACD
- PGZ -0.00
- INCR 0.00
- Stochastic Oscillator
- PGZ 86.67
- INCR 100.00
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.